Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Parisa R KhalighiKylee L MartensAndrew A WhiteShan LiEmily SilgardDeborah FriezeDavid A GarciaAng LiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Our results suggest that rasburicase may be frequently prescribed to treat hyperuricemia unrelated to tumor lysis syndrome in cancer patients. Improved education and adherence to guidelines may improve clinical and economic outcomes associated with rasburicase administration.